Just a couple of months after launching its direct-to-consumer pharmacy service, Eli Lilly (NYSE: LLY) has announced plans to ramp things up significantly. 14 March 2024
A final report for KarXT (xanomeline tartrate/trospium chloride) has been published by influential pricing watchdog The Institute for Clinical and Economic Revi 12 March 2024
With demand for GLP-1 agonists outstripping supply, Zepbound (tirzepatide) developer Eli Lilly (NYSE: LLY) has issued a warning against resorting to counterfeit 8 March 2024
French drugmaker Ipsen has secured a positive reimbursement decision from the UK’s National Institute for Health and Care Excellence (NICE). 7 March 2024
President Joe Biden’s actions to cut prescription drug prices through the Inflation Reduction Act (IRA) and other means have been far from popular with big phar 7 March 2024
A bold move to rip up intellectual property protections for COVID-19 vaccines appears to have been quietly dropped, after the World Trade Organization (WTO) opt 6 March 2024
A pair of big pharma companies have become the latest drugmakers to take aim at the National Institute for Health and Care Excellence (NICE), the cost-effective 5 March 2024
The National Institute for Health and Care Excellence (NICE) has decided not to recommend Xenpozyme (olipudase alfa) as a treatment for acid sphingomyelinase de 5 March 2024
All manufacturers participating in the first cycle of Medicare drug price negotiations have responded with counter offers, according to the US Department of Hea 5 March 2024
In another legal blow for opponents of the Inflation Reduction Act (IRA), a federal judge has now rejected a bid from AstraZeneca to prevent price negotiations 4 March 2024
There is a ray of hope for sickle cell disease (SCD) patients in the UK, after the British health technology assessor re-opened its review into Oxbryta (voxelot 1 March 2024
In the USA, there is growing resistance to a bid from the White House to exercise so-called march-in rights, a process whereby the federal government requires p 27 February 2024
A new partnership will see Japanese pharma major Takeda and India’s Biological E (BE) working together to accelerate access to Qdenga (dengue vaccine). 27 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.